• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Axogen, Inc. - Common Stock (NQ: AXGN )

    16.66 -0.07 (-0.42%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Axogen, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Earnings Preview
    Via Benzinga
    Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
    CytoSorbents CFO Kathleen P. Bloch Retires 
    From CytoSorbents
    Via GlobeNewswire
    AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024
    AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Axogen, Inc. Announces New Leadership Appointments
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Reports Second Quarter 2024 Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
    Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
    From Axogen, Inc.
    Via GlobeNewswire
    AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024
    AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Axogen, Inc Reports First Quarter 2024 Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
    Via Benzinga
    AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
    AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
    From Axogen, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 5, 2024
    Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
    Via Benzinga
    Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
    From Axogen, Inc.
    Via GlobeNewswire
    Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Axogen, Inc.
    Via GlobeNewswire
    Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
    From Axogen, Inc.
    Via GlobeNewswire
    Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales
    U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&P... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Applied Therapeutics, Inc. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.